• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Kewaunee Scientific Corporation

    5/9/25 10:54:08 AM ET
    $KEQU
    Medical Specialities
    Industrials
    Get the next $KEQU alert in real time by email
    SD 1 cy2024formsdconflictminera.htm SD Document

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549
    _________________________
    FORM SD
    _________________________
    Specialized Disclosure Report
    _________________________
    KEWAUNEE SCIENTIFIC CORPORATION
    (Exact name of registrant as specified in its charter)
    _________________________
    Delaware0-5286 38-0715562
    (State or other jurisdiction of
    incorporation or organization)
    (Commission File Number) (IRS Employer
    Identification No.)
    2700 West Front Street
    Statesville, North Carolina
     28677-2927
    (Address of principal executive offices) (Zip Code)

    Donald T. Gardner III; 704-873-7202
    (Name and telephone number, including area code, of the person to contact in connection with this disclosure.)

    Check the appropriate box to indicate the rule pursuant to which this form is being filed, and provide the period to which the information in this form applies:

    ☒ Rule 13p-1 under the Securities Exchange Act (17CFR 240.13p-1) for the disclosure period from January 1 to December 31, 2024.
    ☐ Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended ____.
            




    Section 1 - Conflict Minerals Disclosure

    Item 1.01    Conflict Minerals Disclosure and Report

    Kewaunee Scientific Corporation shares the concerns of Congress and the international business community that profits from the mining of certain minerals (“3TGs,” as defined below) in the Democratic Republic of Congo or its adjoining countries may be aiding human rights abuses. The term “3TGs” refers to columbite-tantalite (coltan), cassiterite, gold, wolframite or their derivatives, which are limited to tantalum, tin and tungsten.

    With respect to the calendar year ended December 31, 2024, we identified several of our products for which 3TGs (as defined above) may be present in and necessary to their functionality or production. Accordingly, we have developed a conflict minerals procedure, as described below, reasonably designed to identify whether the 3TGs in the Covered Products, if any, originated in the Democratic Republic of Congo or an adjoining country (the Republic of the Congo, the Central African Republic, South Sudan, Uganda, Rwanda, Burundi, Tanzania, Zambia or Angola) (the “Covered Countries”), or whether any of the 3TGs in the Covered Countries are from recycled or scrap sources.

    On an annual basis, our product development team reviews a list of our significant vendors and identifies any vendors for which the materials we purchase may contain 3TGs. Through this process, we determined that several of our products may contain small traces of one or more 3TGs. As a result, we have established a process whereby we conduct a country-of-origin inquiry reasonably designed to determine whether 3TGs contained in or used to produce these products, if any, originated in a Covered Country or were from recycled or scrap sources.

    Description of the Company’s Reasonable Country of Origin Inquiry

    To determine the origin of any 3TGs, a survey was sent to all of our identified suppliers whose products may contain them. The survey inquired about the origin of their 3TGs and whether they had a written policy for conflict-free sourcing of 3TGs, among other items. Except as described below, responses received from the survey indicated that any 3TGs in materials provided by our suppliers did not originate from the Covered Countries. In addition to the responses received from our suppliers, management has no reason to believe that any 3TGs in or used in the production of our Covered Products may have originated in the Covered Countries.

    In response to our survey, one supplier identified one potential smelter located in a Covered Country. We have determined that this potential smelter is listed as “Conformant” for having successfully completed an assessment against the applicable Responsible Minerals Initiative Responsible Minerals Assurance Process assessment standard. Our inquiry regarding the origin or source of 3TG contained in our products did not provide sufficient information to conclusively determine the country of origin of 3TG contained in our products that we obtain from this supplier or whether such 3TG came from recycled or scrap sources, or whether the 3TG benefited or financed armed groups, and we cannot ascertain if a Covered Country source was in fact used for the 3TG contained in any of our products containing 3TGs from this supplier.

    If at any time we discover the use of any 3TGs originating from the Covered Countries, we will take appropriate measures to discontinue use of such materials or processes.

    This information is also available on our website at www.kewaunee.com, as well as the SEC’s EDGAR database at www.sec.gov.



    Signature

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this disclosure to be signed on its behalf by the undersigned hereunto duly authorized.

     KEWAUNEE SCIENTIFIC CORPORATION
                                 (Registrant)
    Date: May 9, 2025 By/s/ Donald T. Gardner III
     Donald T. Gardner III
     Vice President, Finance and
    Chief Financial Officer

    Get the next $KEQU alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KEQU

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $KEQU
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Kewaunee Scientific Reports Results for Second Quarter of Fiscal Year 2026

    STATESVILLE, N.C., Dec. 10, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its second quarter ended October 31, 2025. Fiscal Year 2026 Second Quarter Results: Sales during the second quarter of fiscal year 2026 were $70,096,000, an increase of 46.8% compared to sales of $47,764,000 from the prior year's second quarter. Pre-tax earnings for the quarter were $3,453,000 compared to $3,931,000 for the prior year quarter, a decrease of 12.2%. Net earnings were $2,445,000 compared to net earnings of $3,008,000 for the prior year quarte

    12/10/25 4:02:00 PM ET
    $KEQU
    Medical Specialities
    Industrials

    Kewaunee Scientific Announces Successful Debt Refinancing and Full Repayment of Seller Notes From the Company's Acquisition of Nu Aire, Inc.

    STATESVILLE, N.C., Dec. 4, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU), a recognized leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products, today announced its successful debt refinancing and the full repayment of its Seller Notes. On December 4, 2025, Kewaunee Scientific Corporation (the "Company" or "Kewaunee") successfully repaid in full and ahead of schedule its Seller Notes, entered into November 1, 2024, in connection with the Company's acquisition of Nu Aire, Inc. ("Nu Aire"). The Seller No

    12/4/25 4:55:00 PM ET
    $KEQU
    Medical Specialities
    Industrials

    Kewaunee Scientific to Report Results for Second Quarter Fiscal Year 2026

    STATESVILLE, N.C., Nov. 26, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced that the Company plans to release its second quarter fiscal year 2026 financial results on Wednesday, December 10, 2025 after the close of trading. This information will be available on the Company's website www.kewaunee.com after the release. About Kewaunee Scientific Founded in 1906, Kewaunee Scientific Corporation is a recognized global leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products. The Company's pr

    11/26/25 4:02:00 PM ET
    $KEQU
    Medical Specialities
    Industrials

    $KEQU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President, CEO Hull Thomas David Iii sold $81,638 worth of shares (2,177 units at $37.50), decreasing direct ownership by 6% to 33,000 units (SEC Form 4)

    4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

    1/8/26 9:09:31 AM ET
    $KEQU
    Medical Specialities
    Industrials

    Chief Financial Officer Gardner Donald T. Iii sold $75,140 worth of shares (2,000 units at $37.57), decreasing direct ownership by 17% to 9,564 units (SEC Form 4)

    4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

    1/7/26 3:59:57 PM ET
    $KEQU
    Medical Specialities
    Industrials

    President, CEO Hull Thomas David Iii sold $24,790 worth of shares (658 units at $37.67), decreasing direct ownership by 2% to 35,177 units (SEC Form 4)

    4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

    1/2/26 1:03:17 PM ET
    $KEQU
    Medical Specialities
    Industrials

    $KEQU
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gehl Keith M bought $35,000 worth of shares (1,000 units at $35.00), increasing direct ownership by 6% to 18,500 units (SEC Form 4)

    4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

    4/7/25 10:57:11 AM ET
    $KEQU
    Medical Specialities
    Industrials

    Director Gehl Keith M bought $22,500 worth of shares (500 units at $45.00), increasing direct ownership by 3% to 17,500 units (SEC Form 4)

    4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

    3/24/25 4:32:54 PM ET
    $KEQU
    Medical Specialities
    Industrials

    Director Gehl Keith M bought $19,747 worth of shares (403 units at $49.00), increasing direct ownership by 2% to 17,000 units (SEC Form 4)

    4 - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Issuer)

    3/18/25 3:20:26 PM ET
    $KEQU
    Medical Specialities
    Industrials

    $KEQU
    SEC Filings

    View All

    SEC Form 10-Q filed by Kewaunee Scientific Corporation

    10-Q - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Filer)

    12/12/25 9:41:25 AM ET
    $KEQU
    Medical Specialities
    Industrials

    Kewaunee Scientific Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Filer)

    12/10/25 4:09:37 PM ET
    $KEQU
    Medical Specialities
    Industrials

    Kewaunee Scientific Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Filer)

    12/4/25 4:59:35 PM ET
    $KEQU
    Medical Specialities
    Industrials

    $KEQU
    Leadership Updates

    Live Leadership Updates

    View All

    Kewaunee Scientific Announces Appointment of J. Jette Campbell to Board of Directors

    STATESVILLE, N.C., Sept. 11, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU), a recognized leader in the design, manufacture, and installation of laboratory, healthcare, and technical furniture products, announces the appointment of J. Jette Campbell, CPA, to its Board of Directors, effective September 10, 2025. Campbell brings decades of experience guiding organizations through significant growth and transformation. Campbell's impressive career spans leadership roles at global companies such as PepsiCo, Frito-Lay, and Griffin LLC, a DuPont venture. He also

    9/11/25 4:03:00 PM ET
    $KEQU
    Medical Specialities
    Industrials

    $KEQU
    Financials

    Live finance-specific insights

    View All

    Kewaunee Scientific Reports Results for Fiscal Year and Fourth Quarter

    STATESVILLE, N.C., June 25, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its fourth quarter and its fiscal year ended April 30, 2025. Fiscal Year 2025 Fourth Quarter Results Sales during the fourth quarter of fiscal year 2025 were $77,148,000, an increase of 36.1% compared to sales of $56,702,000 from the prior year's fourth quarter. Pre-tax earnings for the quarter were $7,149,000 compared to $1,347,000 for the prior year quarter. Net earnings for the quarter were $4,850,000 compared to net earnings of $11,026,000 for the prio

    6/25/25 6:22:00 PM ET
    $KEQU
    Medical Specialities
    Industrials

    Kewaunee Scientific Reports Results for Third Quarter of Fiscal Year 2025

    STATESVILLE, N.C., March 12, 2025 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its third quarter ended January 31, 2025. Fiscal Year 2025 Third Quarter Results: Sales during the third quarter of fiscal year 2025 were $67,167,000, an increase of 43.6% compared to sales of $46,778,000 from the prior year's third quarter. Pre-tax earnings for the quarter were $1,275,000 compared to $3,515,000 for the prior year quarter, a decrease of 63.7%. Net earnings were $1,354,000 compared to net earnings of $2,521,000 for the prior year quarter.

    3/12/25 4:16:00 PM ET
    $KEQU
    Medical Specialities
    Industrials

    Kewaunee Scientific Reports Results for Second Quarter of Fiscal Year 2025

    STATESVILLE, N.C., Dec. 11, 2024 /PRNewswire/ -- Kewaunee Scientific Corporation (NASDAQ:KEQU) today announced results for its second quarter ended October 31, 2024. Fiscal Year 2025 Second Quarter Results: Sales during the second quarter of fiscal year 2025 were $47,764,000, a decrease of 5.3% compared to sales of $50,436,000 from the prior year's second quarter. Pre-tax earnings for the quarter were $3,931,000 compared to $4,845,000 for the prior year quarter, a decrease of 18.9%. Net earnings were $3,008,000 compared to net earnings of $2,732,000 for the prior year quarter.

    12/11/24 4:04:00 PM ET
    $KEQU
    Medical Specialities
    Industrials

    $KEQU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Kewaunee Scientific Corporation

    SC 13G/A - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Subject)

    11/1/24 9:14:13 AM ET
    $KEQU
    Medical Specialities
    Industrials

    SEC Form SC 13G/A filed by Kewaunee Scientific Corporation (Amendment)

    SC 13G/A - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Subject)

    2/9/24 11:44:29 AM ET
    $KEQU
    Medical Specialities
    Industrials

    SEC Form SC 13G/A filed by Kewaunee Scientific Corporation (Amendment)

    SC 13G/A - KEWAUNEE SCIENTIFIC CORP /DE/ (0000055529) (Subject)

    2/9/24 9:59:14 AM ET
    $KEQU
    Medical Specialities
    Industrials